# AB-RayBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ab-raybio

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: https://www.abraybio.com/
- Latest round: Angel (Jun 13, 2025)
- Investors on record: 3

## About

Founded in 2024 and headquartered in Hangzhou, China, AB-Raybio Therapeutics Co., Ltd., trading as AB-RayBio, focuses on innovative biopharmaceutical solutions for cancer treatment. 
In April 2026, AB-RayBio raised a pre-series A funding led by Fuzhe Technology, with participation from Hangzhou High-Tech Investment and other investors.
The company specializes in the research and development of innovative targeted radiopharmaceuticals, specifically designed to address unmet clinical needs in oncology. The company is currently in the clinical research phase, working on novel therapeutic options for cancer patients and enhancing treatment choices. They utilize a technology platform that includes small molecule discovery, AI-driven peptide high-throughput screening, radiopharmaceutical labeling, quality research, non-clinical evaluation, and rapid clinical translation. The primary end-users are healthcare providers and institutions that treat cancer patients, targeting markets in regions with high cancer prevalence.
The financial operations of the company are structured around partnerships and direct collaborations with healthcare institutions and research organizations. The company engages in B2B transactions, supplying its radiopharmaceutical products to hospitals and cancer treatment centers. Pricing is established based on contracts reflecting the value of their innovative treatments, supporting the delivery of core products designed to enhance therapeutic outcomes for patients with cancer, although specific pricing details and revenue figures are not disclosed.
The pre-series A funds raised will be primarily used for key investments in core pipeline R&D, the establishment of the Haiyan base, and the expansion of the core team, providing technical, industrial, and talent support for the company's development.

## Funding rounds

- Angel, Jun 13, 2025 — HIIG Equity Fund, Hangzhou Gaoxin Technology Venture, Zing Capital

## Investors

- HIIG Equity Fund (https://capitalatlas.ai/funds/hiig-equity-fund) — Angel
- Hangzhou Gaoxin Technology Venture — Angel
- Zing Capital — Angel